간이식 후 C형간염 재발로 발생한 fibrosing cholestatic hepatitis 환자에서 페그인터페론과 리바비린 치료 경험 1예
Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation
0
조회
0
다운로드
1
인용
0
참고문헌
초록
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon α-2a and ribavirin.
Abstract
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon α-2a and ribavirin.
참고문헌 (21)
- Davies SE, "Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis", Hepatology, 13, pp.150~157 (1991)
- Dickson RC, "Quality of life of hepatitis B and C patients after liver transplantation", Clin Transplant, 11, pp.282~285 (1997)
- Schluger LK, "Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation", Hepatology, 23, pp.971~976 (1996)
- Gane EJ, "Long-term outcome of hepatitis C infection after liver transplantation", N Engl J Med, 334, pp.815~820 (1996)
- Delgado J, "Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor?", J Heart Lung Transplant, 18, pp.607~610 (1999)
- Zylberberg H, "Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation", Transplantation, 63, pp.158~160 (1997)
- Delladetsima JK, "Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection", Liver Transpl Surg, 5, pp.294~300 (1999)
- Martin P, "Recurrence of hepatitis C virus infection after orthotopic liver transplantation", Hepatology, 13, pp.719~721 (1991)
- Takahashi T, "Fibrosing cholestatic hepatitis developing after liver transplantation: case report of a patient with HCV-related cirrhosis", Transplant Proc, 35, pp.392~393 (2003)
- Furuta K, "Fibrosing cholestatic hepatitis in a liver transplant recipient with hepatitis C virus infection: a case report", Transplant Proc, 35, pp.389~391 (2003)
- Dixon LR, "Early histologic changes in fibrosing cholestatic hepatitis C", Liver Transpl, 13, pp.219~226 (2007)
- Berenguer M, "Management of hepatitis C virus in the transplant patient", Clin Liver Dis, 11, pp.355~376 (2007)
- Terrault NA, "Treating hepatitis C infection in liver transplant recipients", Liver Transpl, 12, pp.1192~1204 (2006)
- Taga SA, "Cholestatic hepatitis C in liver allografts", Liver Transpl Surg, 4, pp.304~310 (1998)
- Gopal DV, "Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite", Liver Transpl, 9, pp.348~353 (2003)
- Bolkhir A, "Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy", Liver Transpl, 13, pp.309~311 (2007)
- Berg T, "Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin", Gastroenterology, 130, pp.1086~1097 (2006)
- Sanchez-Tapias JM, "TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment", Gastroenterology, 131, pp.451~460 (2006)
- Lee HK, "Fibrosing cholestatic hepatitis: a report of three cases", J Korean Med Sci, 15, pp.111~114 (2000)
- Jung S, "Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine", J Gastroenterol Hepatol, 17, pp.345~350 (2002)
- Oh KB, "Recurrence and management of hepatitis C after liver transplantation", Korean J Hepatol, 9, pp.180~187 (2003)